PMV Pharmaceuticals (PMVP) Assets (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Assets came in at $96.6 million in Q1 2026, down 43.4% YoY from $170.6 million in Q1 2025, and down 17.16% on a QoQ basis from $116.6 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Assets (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Assets data on file, last reported at $96.6 million in Q1 2026.
- Quarterly Assets fell 43.4% year-over-year to $96.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.6 million (down 43.4% YoY) and the FY2025 annual result came in at $116.6 million, down 39.06% from the prior year.
- Assets slipped to $96.6 million in Q1 2026, from $116.6 million in the prior quarter.
- In the past five years, Assets ranged from a high of $315.0 million in Q1 2022 to a low of $96.6 million in Q1 2026.
- A 5-year average of $220.0 million and a median of $237.5 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2024 — Assets slipped 1.93% — and 2026, when it tumbled 43.4%.
- Tracing PMVP's Assets over 5 years: stood at $270.3 million in 2022, then declined by 6.72% to $252.2 million in 2023, then declined by 24.14% to $191.3 million in 2024, then plunged by 39.06% to $116.6 million in 2025, then fell by 17.16% to $96.6 million in 2026.
- The last three Assets figures came in at $96.6 million (Q1 2026), $116.6 million (Q4 2025), and $133.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | 82.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96.56 Mn |
| Dec 31, 2025 | 116.56 Mn |
| Sep 30, 2025 | 133.84 Mn |
| Jun 30, 2025 | 152.86 Mn |
| Mar 31, 2025 | 170.61 Mn |
| Dec 31, 2024 | 191.29 Mn |
| Sep 30, 2024 | 223.50 Mn |
| Jun 30, 2024 | 237.54 Mn |
| Mar 31, 2024 | 236.88 Mn |
| Dec 31, 2023 | 252.15 Mn |
| Sep 30, 2023 | 261.03 Mn |
| Jun 30, 2023 | 242.22 Mn |
| Mar 31, 2023 | 253.96 Mn |
| Dec 31, 2022 | 270.31 Mn |
| Sep 30, 2022 | 284.98 Mn |
| Jun 30, 2022 | 300.56 Mn |
| Mar 31, 2022 | 315.01 Mn |
| Dec 31, 2021 | 331.57 Mn |
| Sep 30, 2021 | 344.18 Mn |
| Jun 30, 2021 | 355.91 Mn |